低分子肝素钠治疗慢性阻塞性肺疾病的临床观察

Clinical Observation on Low Molecular Weight Heparin Sodium in the Treatment of Chronic Obstructive Pulmonary Disease

目的探讨低分子肝素钠治疗慢性阻塞性肺疾病(COPD)患者的临床疗效。方法选取我院2013年1月至2017年12月收治的42例COPD患者,随机分为观察组和对照组各21例。对照组给予常规治疗,观察组在对照组基础上给予低分子肝素钠5 000 IU皮下注射治疗,观察两组患者治疗前后的血气指标、肺功能指标和凝血功能指标及临床疗效。结果与对照组比较,观察组治疗后的PaCO2水平较低, PaO2水平较高, FEV1%pred、 FEV1/FVC较高,红细胞比容、 D-D水平、 APTT较低,差异均有统计学意义(P <0.01)。观察组的总有效率为95.24%,明显高于对照组的71.43%(P <0.05)。结论低分子肝素钠治疗COPD的疗效显著,能够改善患者的血液循环和心肺功能,值得临床推广应用。

Objective To explore the clinical efficacy of low molecular weight heparin sodium in the treatment of patients with chronic obstructive pulmonary disease(COPD). Methods 42 cases of COPD patients admitted to our hospital from January 2013 to December 2017 were selected and randomly divided into observation group and control group, with 21 cases in each group. The control group was given routine treatment, while the observation group was given subcutaneous injection of 5 000 IU low molecular weight heparin sodium on this basis. The indicators of blood gas, lung function and coagulation function before and after treatment, and the clinical efficacy were compared between the two groups. Results Compared with the control group, the PaCO2 level of the observation group after treatment was lower, the PaO2 level was higher, the FEV1%pred and FEV1/FVC were higher, and the erythrocrit, D-D level and APTT were lower(all P<0.01). The total effective rate of the observation group was 95.24%, significantly higher than 71.43% of the control group(P<0.05).Conclusions Low molecular weight heparin sodium has significant curative effect in the treatment of COPD patients, and can improve the blood circulation and cardiopulmonary function of patients, which is worthy of clinical promotion and application.